Bacterial Conjunctivitis Treatment Guidelines
First-Line Treatment Options
- The American Academy of Ophthalmology recommends fluoroquinolone eyedrops, such as moxifloxacin 0.5%, for the treatment of bacterial conjunctivitis due to its broad spectrum coverage and proven efficacy against common ocular pathogens 1
Treatment Selection Based on Severity
- Topical antibiotics are associated with earlier clinical and microbiological remission in patients with mild bacterial conjunctivitis 2
- Single-drug therapy using a fluoroquinolone has been shown to be as effective as combination therapy for mild bacterial conjunctivitis 3
- In resource-limited settings, povidone-iodine 1.25% ophthalmic solution may be considered as an alternative when access to antibiotics is limited 4
Antimicrobial Resistance Considerations
- There has been a sharp increase in resistance of Pseudomonas aeruginosa to moxifloxacin in southern India, from 19% in 2007 to 52% in 2009 1
- Methicillin-resistant S. aureus (MRSA) has been isolated with increasing frequency and is often resistant to many commercially available topical antibiotics 4
- For suspected MRSA infections not responding to fluoroquinolones, consider referral for possible treatment with vancomycin 1
Follow-up Recommendations
- Patients should be advised to return for evaluation in 3-4 days if no improvement is noted, as recommended by the American Academy of Ophthalmology 2
- If there is no improvement after 3-4 days of treatment, consider reevaluating the diagnosis or the possibility of resistant organisms, according to the American Academy of Ophthalmology 6